Oramed Pharmaceuticals Inc (ORMP):企業の財務・戦略的SWOT分析

◆英語タイトル:Oramed Pharmaceuticals Inc (ORMP) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1675
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥17,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Oramed Pharmaceuticals Inc (ORMP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oramed Pharmaceuticals Inc (Oramed) is a pharmaceutical company that carries out research and development of novel pharmaceutical solutions, comprising an oral insulin capsule used for the treatment of people with diabetes, and orally ingestible capsules for delivery of other polypeptides. It developed a novel proprietary platform technology, Protein Oral Delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs and administered only by injection. Its pipeline products are intended for the treatment of type 1 and type 2 diabetes. The company also focuses on the development of combination therapy of insulin and GLP-1 analogs for the management of type 2 diabetes. Oramed is headquartered in New York, the US.

Oramed Pharmaceuticals Inc Key Recent Developments

Jan 30,2020 Oramed appoints Dr. Julio Rosenstock to its Scientific Advisory Board
Jan 28,2020 Oramed patent in Europe to be granted for oral delivery of proteins
Jan 23,2020 Oramed elects Dr. Alexander Fleming to Scientific Advisory Board
Jan 21,2020 Oramed appoints Dr. Jay Skyler to Scientific Advisory Board

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Oramed Pharmaceuticals Inc – Key Facts
Oramed Pharmaceuticals Inc – Key Employees
Oramed Pharmaceuticals Inc – Key Employee Biographies
Oramed Pharmaceuticals Inc – Major Products and Services
Oramed Pharmaceuticals Inc – History
Oramed Pharmaceuticals Inc – Company Statement
Oramed Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Oramed Pharmaceuticals Inc – Business Description
R&D Overview
Oramed Pharmaceuticals Inc – Corporate Strategy
Oramed Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Oramed Pharmaceuticals Inc – Strengths
Oramed Pharmaceuticals Inc – Weaknesses
Oramed Pharmaceuticals Inc – Opportunities
Oramed Pharmaceuticals Inc – Threats
Oramed Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Oramed Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 30, 2020: Oramed appoints Dr. Julio Rosenstock to its Scientific Advisory Board
Jan 28, 2020: Oramed patent in Europe to be granted for oral delivery of proteins
Jan 23, 2020: Oramed elects Dr. Alexander Fleming to Scientific Advisory Board
Jan 21, 2020: Oramed appoints Dr. Jay Skyler to Scientific Advisory Board
Dec 05, 2019: Oramed appoints Dr. Arie Mayer to Board of Directors
Dec 02, 2019: Oramed to present a scientific poster at International Diabetes Federation Congress
Nov 21, 2019: Oramed patent granted in Japan for protease inhibitor, a key component of platform technology
Jul 23, 2019: Oramed Pharmaceuticals: Departure of Directors or certain officers
Jul 02, 2019: Oramed announces Xiaoming Gao joins board of directors
Mar 28, 2019: Oramed patent allowed in the U.S. for key aspect of its oral delivery technology
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Oramed Pharmaceuticals Inc, Key Facts
Oramed Pharmaceuticals Inc, Key Employees
Oramed Pharmaceuticals Inc, Key Employee Biographies
Oramed Pharmaceuticals Inc, Major Products and Services
Oramed Pharmaceuticals Inc, History
Oramed Pharmaceuticals Inc, Subsidiaries
Oramed Pharmaceuticals Inc, Joint Venture
Oramed Pharmaceuticals Inc, Key Competitors
Oramed Pharmaceuticals Inc, Ratios based on current share price
Oramed Pharmaceuticals Inc, Annual Ratios
Oramed Pharmaceuticals Inc, Annual Ratios (Cont...1)
Oramed Pharmaceuticals Inc, Interim Ratios
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Oramed Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Oramed Pharmaceuticals Inc, Performance Chart (2015 - 2019)
Oramed Pharmaceuticals Inc, Ratio Charts
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Oramed Pharmaceuticals Inc (ORMP):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Capgemini SE:企業のM&A・事業提携・投資動向
    Capgemini SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Capgemini SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Quark Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Quark Pharmaceuticals Inc (Quark), a subsidiary of SBI Biotech Co Ltd, is a clinical-stage pharmaceutical company in the development of novel RNAi-based therapeutics. It offers under development products which include PF-655, a synthetic siRNA which is used for the treatment of diabetic macu …
  • Varian Medical Systems Inc (VAR):企業の財務・戦略的SWOT分析
    Varian Medical Systems Inc (VAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • AVX Corp (AVX):企業の財務・戦略的SWOT分析
    AVX Corp (AVX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • I-O Data Device, Inc. (6916):企業の財務・戦略的SWOT分析
    I-O Data Device, Inc. (6916) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Biogen Inc (BIIB)-製薬・医療分野:企業M&A・提携分析
    Summary Biogen Inc (Biogen) is a global biotechnology company that manufactures and markets drugs for the treatment of neurodegenerative diseases and rare and autoimmune disorders. Its marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbry …
  • BrainStorm Cell Therapeutics Inc (BCLI):企業の財務・戦略的SWOT分析
    Summary BrainStorm Cell Therapeutics Inc (BrainStorm Cell Therapeutics) formerly Golden Hand Resources Inc is a biotechnology company which develops autologous stem cell therapies for neurodegenerative diseases. Its pipeline mesenchymal stem cell products are being developed based on cell therapy pl …
  • Telenet Group Holding NV:企業の戦略・SWOT・財務分析
    Telenet Group Holding NV - Strategy, SWOT and Corporate Finance Report Summary Telenet Group Holding NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Ardelyx Inc (ARDX):製薬・医療:M&Aディール及び事業提携情報
    Summary Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in …
  • Frontera Energy Corp (FEC):企業の財務・戦略的SWOT分析
    Frontera Energy Corp (FEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Sarovar Hotels Private Limited:企業の戦略・SWOT・財務情報
    Sarovar Hotels Private Limited - Strategy, SWOT and Corporate Finance Report Summary Sarovar Hotels Private Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Hays plc (HAS):企業の財務・戦略的SWOT分析
    Hays plc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • University of Maryland Medical Center Corp:企業の戦略的SWOT分析
    University of Maryland Medical Center Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • James Latham Plc (LTHM):企業の財務・戦略的SWOT分析
    James Latham Plc (LTHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Etihad Airways:企業のM&A・事業提携・投資動向
    Etihad Airways - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Etihad Airways Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Sinotrans Ltd:企業の戦略・SWOT・財務情報
    Sinotrans Ltd - Strategy, SWOT and Corporate Finance Report Summary Sinotrans Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • DURECT Corp (DRRX)-医療機器分野:企業M&A・提携分析
    Summary DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s …
  • SGL Carbon SE:企業の戦略・SWOT・財務情報
    SGL Carbon SE - Strategy, SWOT and Corporate Finance Report Summary SGL Carbon SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Qiagen NV (QIA):企業の財務・戦略的SWOT分析
    Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • PT Perusahaan Gas Negara (Persero) Tbk (PGAS):企業の財務・戦略的SWOT分析
    PT Perusahaan Gas Negara (Persero) Tbk (PGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆